Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer

BACKGROUND: The survival benefit for single-agent anti–epidermal growth factor receptor (egfr) therapy compared with combination therapy with irinotecan in KRAS wildtype (wt) metastatic colorectal cancer (mcrc) patients in the third-line treatment setting is not known. The objective of the present s...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kennecke, H., Chen, L., Blanke, C.D., Cheung, W.Y., Schaff, K., Speers, C.
Format: Artigo
Jezik:Inglês
Izdano: Multimed Inc. 2013
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3851344/
https://ncbi.nlm.nih.gov/pubmed/24311948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.20.1600
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items